Vaccine-maker Novavax kicks off trial for combined Covid-19/flu jab – https://t.co/vRNDpIpI8s –
American vaccine-maker Novavax has started its early stage trial of a vaccine which combines an as-yet-unapproved Covid-19 shot with the company’s NanoFlu influenza jab.
… pic.twitter.com/UkKjeKwvAJ— kashco.co.uk (@Kashco_co_uk) September 8, 2021
美国生技药厂诺瓦瓦克斯（Novavax）今天宣布，旗下由流感疫苗和COVID-19疫苗结合而成的新疫苗NanoFlu/NVX-CoV2373，已展开初期临床试验。
路透社报导，诺瓦瓦克斯先前指出，NanoFlu/NVX-CoV2373的临床前研究显示，这支疫苗不仅对于A型和B型流感能引起很强的免疫反应，对COVID-19（2019冠状病毒疾病）的SARS-CoV-2病毒也能产生防护力。
“Combination of these two vaccines… may lead to greater efficiencies for the healthcare system and achieve high levels of protection against Covid-19 and influenza with a single regimen,” Novavax’s president of research and development Gregory Glenn said in a statement.
The firm has been touted as a leader in the race to safely and effectively combine flu and Covid-19 vaccines. Novavax said in May that it expects seasonal flu and Covid-19 combo vaccines to be vitally important in controlling the spread of the pandemic.
来源: 联合新闻
1,496 views
